Insulet leads with $50M round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Insulet
|
$50M
|
OrbiMed Advisor |
The funding will be to expand capacity to meet the demand for the OmniPod Insulin Management System. |
|
Precision Therapeutics
|
$20M
|
Quaker BioVentures |
Precision will use some of the money to commercialize a diagnostic tool for selecting the right chemotherapy treatment for patients. It will also fund new trials in ovarian cancer research. |
|
Supernus Pharmaceuticals
|
$17.5M
|
New Enterprise Associates |
The funding will help the startup use its patents to improve its own portfolio and to partner with other pharmaceutical companies. |
|
Aesthera Corp.
|
$11M
|
Kleiner Perkins Caufield & Byers |
Aesthera will continue the company's R&D efforts for its Photopneumatic Technology and will further expand global sales channels and marketing efforts. |
|
Acologix
|
$4.5M
|
Ascent Biomedical Ventures |
The money is earmarked for a Phase III trial of AC-820, an experimental therapy for uremic pruritus in dialysis patients. |